Full year revenue and EBITDA in line with guidance Accelerating product development post-COVID-19 to become a leading global clinical diagnostic company in infectious diseases Paris, France and Eastleigh, UK 27 April 2023...

Full year revenue and EBITDA in line with guidance Remain focused on post-COVID-19 growth strategy to become a leading global clinical diagnostics company in infectious diseases Paris, France and Eastleigh, UK –...

Paris, France and Eastleigh, UK – 7 Dec 2022 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that Edwin Snape has informed the Board...

Paris, France and Camberley, UK – 10 November 2022 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that David Allmond is stepping down as...

Significant progress against post-COVID-19 growth strategy to offset expected decline in COVID-19 sales Paris, France and Camberley, UK – 29 September 2022 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international...